Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents

Definitions

• the present invention relates to a new pseudopolymorph of desloratadine. More specifically, the present invention relates to a new pseudopolymorphic form of desloratadine formed with carbon dioxide of the Formula
• IV. is a known antihistamine drag, which is an active metabolite of the compound 8-chloro-6,ll-dihydro-ll-(l-ethoxy-carbonyl-4- piperilydene)-5H-benzo[5,6]cyclohepta[l .2-b]pyridine (INN name: loratadine) of the formula
• the ethoxycarbonyl group of the loratidine of the formula V is eliminated by boiling in a mixture of ethanol, water and sodium hydroxide for 24 hours.
• the product is obtained as an acetic acid salt after extraction with chloroform.
• Desloratadine acetate is converted into the free base by reacting with a base, whereupon the crude product is recrystallized from a mixture of benzene and hexane.
• ⁇ -chloro-6,11-dihydro-l 1-(1- methyl-4-piperilydene)-5H-benzo[5,6]cyclohepta[l,2- bjpyridine is demethylated by reacting with bromo cyane, whereupon the produced 1-cyano compound is hydrolysed by refiuxing for 20 hours in a mixture of concentrated hydrochloric acid and acetic acid. After removing the solvents desloratadine base is prepared from the residue by reacting with base. The crude product is purified by recrystallisation from hexane until its melting point rises to 149-151 0 C.
• Hungarian published patent application No. POO/04701 relates to salts of desloratadine with one ore two mole of acids and the preparation thereof.
• desloratadine of the formula IV is prepared by elimination of the ethoxycarbonyl group in the position 1 of the loratadine of the formula V by boiling in concentrated mineral acids, preferably in 60-80% of sulphuric acid at 12O 0 C for 6-8 hours.
• Desloratadine salts in a ratio of 1 :2 of desloratadine to acid prepared according to the Hungarian patent application No. P 00/04701 are unstable. According to our experience the stochiometry of these salts is changed during their storage because of the partly eliminated acidic compounds.
• the preparation of desloratadine salts in a molar ratio of 1 : 1 is more preferable than that of salts in a molar ratio of 1 :2.
• the essential condition for the preparation of these salts is the use of sufficently pure desloratadine base of the formula IV, which can be obtained only by appropriate purification methods after the desethoxycarbonylation reaction.
• the object of present invention is the preparation of a new desloratadine pseudopolymorph suitable for use in the preparation of high purity desloratidine base or high purity desloratine salts.
• the present invention relates to a pseudopolymorph of desloratadine formed with carbon dioxide of the formula I, characterized by its X-ray diffractogram according to diagram
• a process for the preparation of the above mentioned pseudopolymoph of desloratadine formed with carbon dioxide of the formula I which comprises a.) reacting a solution of desloratadine of the formula IV in an organic solvent with carbon dioxide or, b) decarboxyethylating loratidine of the formula V in a solution of 2-methoxyethanol or 2-ethoxyethanol with an alkali metal hydroxide, whereupon reacting the obtained desloratadine of the formula IV with carbon dioxide in an organic solvent.
• the present invention is based on the recognition, that during the reaction of desloratadine of the formula IV with carbon dioxide in an organic solvent an adduct of 2 moles of desloratadine and 1 mole of carbon dioxide of the formula I is precipitated.
• This is a new pseudopolymorphic form of desloratadine.
• the new pseudopolymorphic form formed with carbon dioxide is very pure according to HPLC examinations. Carbon dioxide forms adduct only with desloratadine, meanwhile the amine type contaminations remain in the
• mother liquor and can be easily separated from the desired adduct by filtration or centrifugation.
• the X-ray diffractogram shown in the diagram 1 of the psedopolymorph formed with carbon dioxide is absolutely different from the X-ray difractograms of the Pl and P2 polymorphs (diagram 2. and 3.) of desloratadine.
• the X-ray powder diffractograms were made using a BRUKER D8 ADVANCED X-ray powderdiffractometer under the following circumstances:
• Sample flat surface, unpulverised , stored and measured at room temperature.
• the infrared spectra of the known Pl and P2 polymorphs are made in solid phase and shown in the diagrams 5 and 6.
• the infrared spectrum of the pseudopolymorphs of desloratadine formed with carbon dioxide according to the diagaram 4 has significant differences as compared with infrared spectra of polymorphs Pl and P2.
• the pseudopolymorph does not deliver carbon dioxide upto a temperature of 12O 0 C and according to X-ray crystallographical experiments its crystal structure remains unchanged. Decomposition begins near its melting point, at 14O 0 C, where the compound of the formula I delivers calculated amount of carbon dioxide.
• the reaction is carried out in a solution formed with an ester, ether, or in a mixture of an ester and a lower aliphatic alcohol or in a mixture of an ether and a lower aliphatic alcohol.
• the reaction is carried out in ethyl acetate, tetrahydrofurane, diethyl ether, preferably a mixture of ethyl acetate and methanol, a mixture of ethyl acetate and ethanol, a mixture of tetrahydrofurane and methanol, a mixture of diethyether and ethanol, or a mixture of diethyether and methanol. More preferably it is carried out in a media containing ethyl acetate.
• the process can be carried out by introducing gaseous carbon dioxide or by addition of dry ice to a solution of desloratadine formed with an organic solvent.
• the reaction of desloratadine of the formula IV and carbon dioxide is accomplished between room temperature and 40 0 C, preferably at room temperature.
• the pseudopolymorph of the formula I can be isolated by filtration or centrifugation.
• the product is very pure, additional purification is unnecessary.
• loratadine of the formula V is decarboxyethylated with alkali metal hydroxide in a solution of 2-methoxyethanol or 2-ethoxyethanol, the desloratadine of the formula IV obtained is dissolved in an organic solvent and reacted with carbon dioxide.
• alkali metal hydroxide sodium hydroxide or potassium hydroxide can be used.
• the reaction can be carried out under heating, preferably at the boiling point of the solvent. On completion of the reaction 2-methoxyethanol or 2- ethoxyethanol is evaporated, the residue is dissolved in an organic solvent.
• the solvents enumerated according to the process a), preferably ethyl acetate can be used as organic solvents.
• the solution is reacted similarly to the process a) with carbon dioxide.
• process b) after elimination of the ester group the 2-methoxyethanol or 2- ethoxyethanol solvent is evaporated, the residue is dissolved in ethyl acetate, carbon dioxide is introduced or dry ice is added to the obtained solution and the pseudopolymorph of the formula I is separated by filtration or centrifugation.
• alkali metal hydroxide sodium hydroxide or potassium hydroxide can be used.
• the reaction can be carried out under heating, preferably at the boiling point of the solvent.
• the reaction time is short and it takes 1-3 hours.
• 2-methoxyethanol or 2- ethoxyethanol is removed, the residue obtained is dissolved in an organic solvent, preferably in ethyl acetate. After evaporation of the organic solvent desloratadine base is obtained.
• Vl wherein X stands for an anion and n is 1 or 2, which comprises reacting the solution of a pseudopolymorph salt of desloratadine formed with carbon dioxide of the formula I in an organic solvent with a solution of the corresponding acid formed with an organic solvent.
• hydrochloric acid hydrobromic acid
• sulfuric acid methanesulfonic acid
• benezenesulfonic acid maleic acid or fumaric acid
• maleic acid or fumaric acid can be used as acid.
• the acid is used in an approximately equimolecular amount, based on the pseudopolymorph of the formula I.
• the acid is used in at least a molar ratio of 2:1, preferably between 2 : 1 -3 : 1 , based on pseudopolymorph of the formula I.
• Esters e.g. ethyl acetate or alcohols e.g. methanol or ethanol can be used as solvent.
• reaction of the compound of the formula I with the acid is carried out between room temperature and 40 0 C, preferably at room temperature.
• a significant advantage of the present invention is that desloratadine of the formula IV or desloratadine salts of the formula VI can be prepared in high purity. This is due to the general fact that the pseudopolymorph of desloratadine formed with carbon dioxide of the formula I can be prepared in a high purity which is suitable for pharmaceutical use without further purification.
• the preparation of the adduct of the formula I is a more effective purification than a recrystallisation step. This is so because during the elimination of carbethoxy group in course of the preparation of desloratadine from loratadine small amounts of basic by-products are produced which do not form adducts with carbon dioxide and, therefore remain in the mother-lye after filtration of the adduct of the formula I.
• compositions comprising as active ingredient a pseudopolymorph of desloratadine of the Formula I in admixture with inert pharmaceutically acceptable carriers and/or auxiliary agents.
• compositions according to the present invention can be prepared in conventional forms in therapy.
• compositions according to the present invention can be preferably administered orally or parenterally.
• the oral compositions can be e.g. tablets, capsules, coated tablets, solutions, syrups, suspensions or emulsions.
• the parenteral compositions can be preferably intravenous or intramuscular administered injections.
• the pharmaceutical compositions can contain usual pharmaceutically acceptable carriers and/or auxiliary agents.
• pharmaceutically acceptable carrier for example magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextose, starch, gelatine, tragakant, methyl cellulose, sodium carboxymethylcellulose, wax with low melting point, cocoa butter etc. can be used.
• capsules carrier is often serves as capsule material, whereby additional carrier is not necessary.
• Further oral dosage forms are sachets and homge.
• the tablets, powders, capsules, pellets, sachets and homges are specially useful as solid dosage forms.
• Waxes with low melting point can be used as carriers for suppositories.
• the wax is melted, the active ingredient is admixed with the melt and homogenized.
• the melted, homogenized mixture is then poured into mould and allowed to cool and solidify.
• Tablets can be prepared by admixing the active ingredient with suitable carriers in an appropriate ratio and pressing the mixture into tablets of a desired form and size.
• Powders are prepared by admixing the finely powdered active ingredient with finely powdered carriers.
• Liquid dosage forms can be solutions, suspensions and emulsions, from which the active ingredient can be release in a sustained relaese if desired.
• Solutions formed with water or a mixture of water and propyleneglycol are preferable.
• Liquid dosage forms suitable for parenteral administration are prepared preferably in a mixture of water and ethyleneglycol.
• Aqueous liquid dosage forms suitable for oral administration can be prepared by dissolving the active ingredient in water, whereupon suitable colourants aroma, stabilisers and thickeners are added, depending on the requirements of use.
• Aqueous suspensions suitable for oral administration can be prepared by suspending the active ingredient in water in the presence of a compound having high viscosity e.g. natural or synthetic gums, resins, methyl cellulose, carboxymethylcellulose sodium or other known suspending agents.
• a compound having high viscosity e.g. natural or synthetic gums, resins, methyl cellulose, carboxymethylcellulose sodium or other known suspending agents.
• liquid dosage form An other group of solid dosage forms is transformed into a liquid dosage form immediately before use and which is administered as an oral liquid composition.
• the liquid forms can be solutions, emulsions or suspensions, comprising in addition to the active ingredient colourants, aromas, stabilisers,
• buffers natural or synthetic sweeteners, dispersing agents, thickeners etc.
• the pharmaceutical compositions according to the present invention can be prepared as unit dosage forms.
• the unit dosage forms contain the desirable amount of the active ingredient. These can be marketed as packages, comprising separated amounts of the dosage forms (e.g. packed tablets, capsules, powder in ampoules or bottles).
• the unit dosage form may be capsule, tablet, sachet, losenge and also package containing the appropriate number of unit dosages.
• compositions according to the present invention can be prepared by admixing the pseudopolymorph of desloratadine of the formula I with inert pharmaceutically acceptable earners and/or auxliary agents.
• compositions according to the present invention can be prepared by using conventional processes of the pharmaceutical industry.
• a process for the treatment of allergy which comprises administering the pseudopolymorph of the desloratadine of the formula I to a patient in need of said treatment.
• the white crystalline suspension is cooled to 5 0 C whereupon the mixture is stirred for an additional hour, filtered, the crystals are washed with ethyl acetate and dried at 60 0 C.
• a mixture of 100 ml of 2-methoxyethanol (methylcellosolve) 10 ml of an aqueous 40% sodium hydroxide solution, 2.5 g of sodium hydroxide and 12.5 g (32.65 moles) of loratadine are weighed in a vessel equipped with vigorous stirrer. The mixture is boiled for three hours. The end of the reaction is monitored with TLC.
• the base content of the pale yellow solution is determined, whereupon a solution of an equimolecular amount of hydrogen bromide in ethyl acetate is added.
• the white crystalline product is filtered at 0 0 C, washed with ethanol.
• the suspension is stirred for 3 hours, cooled to 0 0 C, filtered under cooling and washed with ethanol.
• hydrochloric acid is replaced by a solution of 4.05 g (50 mmoles) of hydrogen bromide in ethanol.
• the suspension is stirred for 3 hours, cooled to 0 0 C 5 filtered under cooling and washed with ethanol.
• salt formation is carried out by using a solution of 1.96 g (20mmoles) of sulphuric acid in ethanol at 20-25 0 C. The suspension is stirred for 3 hours, cooled to 0 0 C. filtered under cooling and washed with ethanol.
• salt formation is carried out by using a solution of 2.02 g (21 mmoles) of methanesulphonic acid in ethanol at 20-25 0 C. The suspension is stirred for 3 hours, cooled to 0 0 C 5 filtered under cooling and washed with ethanol.
• salt formation is carried out by using a solution of 3.34 g (21 mmoles) of benzenesulphonic acid in ethanol at 20-25 0 C. The suspension is stirred for two hours, cooled to 0 0 C, filtered under cooling and washed with ethanol.
• the product is crystallised under cooling and scratching.
• the suspension is stirred for two hours at 0 0 C, filtered and washed with ethanol.
• the mixture is homogenized and pressed to tablets.
• the mixture is homogenized and pressed to tablet.
• the mixture is homogenized and pressed to tablet.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pulmonology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Grain Derivatives (AREA)
• Dairy Products (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=89986128

Family Applications (1)

Country Status (9)

Families Citing this family (4)

Family Cites Families (6)

• 2005
  • 2005-07-07 HR HR20070025A patent/HRP20070025A2/xx not_active Application Discontinuation
  • 2005-07-07 EP EP05763423A patent/EP1817307A2/en not_active Withdrawn
  • 2005-07-07 RS RSP-2007/0008A patent/RS20070008A/sr unknown
  • 2005-07-07 WO PCT/HU2005/000073 patent/WO2006003479A2/en not_active Ceased
  • 2005-07-07 EA EA200700208A patent/EA011894B1/ru not_active IP Right Cessation
  • 2005-07-07 SK SK5011-2007A patent/SK50112007A3/sk unknown
  • 2005-07-07 CZ CZ20070098A patent/CZ200798A3/cs unknown
  • 2005-07-07 PL PL381813A patent/PL381813A1/pl not_active Application Discontinuation
• 2007
  • 2007-02-06 BG BG109814A patent/BG109814A/bg unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events